Seeking information about the ABBOTT ID NOW test platform used to diagnose COVID-19.

Apparently Abbott purchased the analyzer business from Alere Inc, in 2018 that had developed the analyzer to provide point-of-contact in vitro diagnostics (IVD) of influenza A & B.

Published evaluations of the effectiveness of the Alere product analysis placed the sensitivity in the low 90% range with influenza A&B, and lower yet for specificity (distinguishing between A & B)

Now that the test analyzer is being utilized for COVID-19 diagnosis, I had some questions:

What is the cost of the analyzer, how many analyzers (repurposed for COVID-19 detection) are already in the field and finally what is the S&S for this analyzer when coupled with the COVID-19 specimen acquisition/test reagent kit?

| |

Your Answer

By clicking “Post Your Answer”, you agree to our terms of service, privacy policy and cookie policy

Browse other questions tagged or ask your own question.